Примери за използване на IBR inactivated на Английски и техните преводи на Български
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Computer
What is CattleMarker IBR Inactivated?
CattleMarker IBR Inactivated fulfils the criteria for an effective IBR marker vaccine and provides the full therapeutic benefit.
Provide a contingency plan in the unlikely circumstance that BNP reports occur that involve CattleMarker IBR Inactivated vaccinated dams.
CattleMarker IBR Inactivated is produced on the same bovine cell line and is adjuvanted with the same highly potent adjuvant as PregSure BVD.
The CVMP was asked to considerthe issues raised by Germany and conclude whether marketing authorisations for CattleMarker IBR Inactivated should be granted.
GE deleted IBR vaccines such as CattleMarker IBR Inactivated are“DIVA vaccines”, differentiating infected from vaccinated animals.
The MAH proposed a post-marketing pharmacovigilance surveillance program utilising its usual pharmacovigilance system for the monitoring of animals vaccinated with CattleMarker IBR Inactivated.
Zoetis Belgium SA submitted an application for CattleMarker IBR Inactivated for mutual recognition on the basis of the initial authorisation granted by Belgium.
CattleMarker IBR Inactivated is an inactivated infectious bovine rhinotracheitis(IBR) vaccine which contains inactivated glycoprotein E(gE) negative bovine herpes virus 1(BoHV-1), strain Difivac.
Send out a letter to all customers receiving the CattleMarker IBR Inactivated for the first time with additional information to raise awareness for possible BNP cases.
CattleMarker IBR Inactivated emulsion for injection for cattle(thereafter called CattleMarker IBR Inactivated) is an inactivated infectious bovine rhinotracheitis(IBR) vaccine which contains glycoprotein E(gE) negative bovine herpes virus 1(BoHV-1), strain Difivac.
The abovementioned study results should be provided to the relevant national competent authorities for assessment prior to placing CattleMarker IBR Inactivated on the EU market and within 24 months of the Commission Decision.
CattleMarker IBR Inactivated has the same highly potent adjuvant, Procision-A, and is grown on the same bovine-derived kidney cell line(MDBK) as PregSure BVD.
The marketing authorisation holder shall conduct a study to assess the potential booster of CattleMarker IBR Inactivated on any MHC-I or opsonizing alloantibody responses in cattle previously vaccinated using PregSure BVD.
CattleMarker IBR Inactivated contains the same adjuvant Procision-A as PregSure BVD and the virus production also utilises a bovine-derived kidney cell line(MDBK).
In a hyperimmunisation study it has been demonstrated that these remaining ANAS from the manufacturing process of CattleMarker IBR Inactivated did not trigger the production of alloantibodies at a level similar to this of animals hyperimmunised with PregSure BVD.
Prior to placing CattleMarker IBR Inactivated on the EU market the results should be submitted to the national competent authorities to be assessed by the authorities to their satisfaction.
Since the issues raised by Germany remained unresolved,the Member States concerned failed to reach agreement regarding the marketing authorisation CattleMarker IBR Inactivated and consequently the matter was referred to the CVMP on 29 September 2015 under Article 33(4) of Directive 2001/82/EC.
Overall, the benefit-risk balance for CattleMarker IBR Inactivated emulsion for injection is considered positive, subject to the conduct of additional studies and the implementation of further measures specified in a RMP.
The Agency's Committee for Medicinal Products for Veterinary Use(CVMP) concluded that, subject to conditions relating to risk mitigation and surveillance measures,the marketing authorisation granted in Belgium for CattleMarker IBR Inactivated can be recognised in other Member States of the EU.
However the manufacturing process of CattleMarker IBR Inactivated leads to an amount of remnant of ANAS(e.g. MDBK cell debris) lower than the one of PregSure BVD.
Which will be included in a risk management plan and are deemed adequate and proportionate to the identified risk of development of BNP;the CVMP has recommended the granting of the marketing authorisation for CattleMarker IBR Inactivated emulsion for injection for cattle subject to conditions affecting the marketing authorisations as set out in Annex IV.
In a hyperimmunisation study, repeated injections of CattleMarker IBR Inactivated did not trigger the production of alloantibodies at a level similar to this of animals hyperimmunised with PregSure BVD.
On 17 March 2016, the European Medicines Agency(the Agency) completed an arbitration procedure following a disagreement among Member States of the European Union(EU)regarding the authorisation of the medicine CattleMarker IBR Inactivated emulsion for injection for cattle(thereafter called CattleMarker IBR Inactivated).
Data has been provided to demonstrate that CattleMarker IBR Inactivated, unlike PregSure BVD, has a reduced amount of immunologically significant amount of ANAS remaining from its manufacturing process on the bovine derived kidney cell line in the final product.
Furthermore, the MAH has made post authorisation commitments to set a maximum level of total proteins for batch release andto perform two additional studies in order to investigate possible interactions of vaccinations with CattleMarker IBR Inactivated in animals previously vaccinated with PregSure BVD or other vaccines.
In addition to the usual pharmacovigilance system for the monitoring of animals vaccinated with CattleMarker IBR Inactivated, to conduct thorough investigations for any unexplained mortality in the offspring of vaccinated animals following documented use of CattleMarker IBR Inactivated.
Based on evaluation of the currently available data and the scientific discussion within the Committee, the CVMP concluded that subject to the conduct of additional studies andthe implementation of further measures specified in a Risk Management Plan the marketing authorisation for CattleMarker IBR Inactivated should be granted in all concerned Member States.
The potential risk deriving from the intended use of CattleMarker IBR Inactivated to trigger BNP is associated with the composition and manufacture of the vaccine and more specifically with the amount of Antigens Not related to the Active Substance(ANAS) and is also linked to the use of the vaccine in female cattle subject to repeated vaccinations.
During the MRP Germany raised a concern about the immunological safety of CattleMarker IBR Inactivated, as the composition of this product is similar to PregSure BVD, a vaccine which has been shown to induce a long-lasting allogeneic antibody response which has been associated with Bovine Neonatal Pancytopenia(BNP), a neonatal alloimmune disease, in the progeny of vaccinated dams.